Predicting survival in pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management …
RL Benza, DP Miller, M Gomberg-Maitland, RP Frantz… - Circulation, 2010 - Am Heart Assoc
Background— Factors that determine survival in pulmonary arterial hypertension (PAH) drive
clinical management. A quantitative survival prediction tool has not been established for …
clinical management. A quantitative survival prediction tool has not been established for …
Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry
…, HW Farber, AE Frost, RJ Barst, RL Benza… - Chest, 2010 - Elsevier
Background The Registry to EValuate Early And Long-term pulmonary arterial hypertension
disease management (REVEAL Registry) was established to provide updated …
disease management (REVEAL Registry) was established to provide updated …
The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis
…, FJ Giordano, PK Shah, JT Willerson, RL Benza… - Circulation, 2003 - Am Heart Assoc
Background— Recombinant human vascular endothelial growth factor protein (rhVEGF)
stimulates angiogenesis in animal models and was well tolerated in Phase I clinical trials. VIVA (…
stimulates angiogenesis in animal models and was well tolerated in Phase I clinical trials. VIVA (…
An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry
RL Benza, DP Miller, RJ Barst, DB Badesch, AE Frost… - Chest, 2012 - Elsevier
… the following conflicts of interest: Dr Benza has received honoraria from Actelion Pharmaceuticals
Ltd; … Dr Benza has received honoraria for his service on the REVEAL Registry Steering …
Ltd; … Dr Benza has received honoraria for his service on the REVEAL Registry Steering …
Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial
…, U Elkayam, A Barbagelata, JK Ghali, RL Benza… - Jama, 2004 - jamanetwork.com
ContextNearly 1 million hospitalizations for chronic heart failure occur yearly in the United
States, with most related to worsening systemic congestion. Diuretic use, the mainstay therapy …
States, with most related to worsening systemic congestion. Diuretic use, the mainstay therapy …
Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial
VV McLaughlin, RL Benza, LJ Rubin… - Journal of the American …, 2010 - jacc.org
Objectives : This study assessed the efficacy and safety of inhaled treprostinil in pulmonary
arterial hypertension (PAH) patients receiving therapy with either bosentan or sildenafil. …
arterial hypertension (PAH) patients receiving therapy with either bosentan or sildenafil. …
Heart failure etiology and response tomilrinone in decompensated heart failure: Results from the OPTIME-CHF study
GM Felker, RL Benza, AB Chandler… - Journal of the American …, 2003 - jacc.org
Objectives : The goal of this study was to assess the interaction between heart failure (HF)
etiology and response to milrinone in decompensated HF. Background : Etiology has …
etiology and response to milrinone in decompensated HF. Background : Etiology has …
Pulmonary arterial hypertension: epidemiology and registries
MD McGoon, RL Benza, P Escribano-Subias… - Journal of the American …, 2013 - jacc.org
Registries of patients with pulmonary arterial hypertension (PAH) have been instrumental in
characterizing the presentation and natural history of the disease and provide a basis for …
characterizing the presentation and natural history of the disease and provide a basis for …
The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension
RL Benza, M Gomberg-Maitland, DP Miller, A Frost… - Chest, 2012 - Elsevier
Background In pulmonary arterial hypertension (PAH), survival predictions can be important
for optimization of therapeutic strategies. The present study aimed to validate a quantitative …
for optimization of therapeutic strategies. The present study aimed to validate a quantitative …
[HTML][HTML] Predicting survival in patients with pulmonary arterial hypertension: the REVEAL risk score calculator 2.0 and comparison with ESC/ERS-based risk …
RL Benza, M Gomberg-Maitland, CG Elliott, HW Farber… - Chest, 2019 - Elsevier
Background Pulmonary arterial hypertension is a progressive, fatal disease. Published treatment
guidelines recommend treatment escalation on the basis of regular patient assessment …
guidelines recommend treatment escalation on the basis of regular patient assessment …